[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371211-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371211-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-treatment-strategy-targeting-interleukin-6-induced-by-cancer-associated-fibroblasts-for-peritoneal-metastasis-of-gastric-cancer","Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer","","Cancer-associated fibroblasts (CAFs) are central to the tumor microenvironment of peritoneal metastasis in gastric cancer, promoting progression and spread through interleukin-6 (IL-6) secretion. The study evaluated IL-6’s role and tested whether anti-IL-6 receptor antibody (anti-IL-6RAb) could suppress peritoneal metastasis. Clinical immunohistochemistry, in vitro co-culture findings, and an orthotopic murine model showed IL-6 correlates with α-SMA, predicts poor prognosis, and links CAFs to metastasis establishment and progression via IL-6 blockade.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-treatment-strategy-targeting-interleukin-6-induced-by-cancer-associated-fibroblasts-for-peritoneal-metastasis-of-gastric-cancer/371211/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-treatment-strategy-targeting-interleukin-6-induced-by-cancer-associated-fibroblasts-for-peritoneal-metastasis-of-gastric-cancer/371211.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do cancer-associated fibroblasts play in gastric cancer peritoneal metastasis?","Question",{"text":63,"@type":64},"CAFs contribute to tumor progression and metastasis in the peritoneal tumor microenvironment by secreting interleukin-6 (IL-6).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are IL-6 and α-SMA related in clinical gastric cancer samples?",{"text":68,"@type":64},"IL-6 expression significantly correlates with α-SMA expression, a marker related to CAFs, and higher IL-6 in primary tumors is associated with poor prognosis.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does anti-IL-6 receptor antibody inhibit peritoneal metastasis in some models but not others?",{"text":72,"@type":64},"Anti-IL-6RAb inhibited progression of peritoneal metastasis in orthotopic models where gastric cancer cells were cocultured with fibroblasts, but it did not inhibit models consisting of gastric cancer cells alone, indicating dependence on CAF-derived IL-6.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371211,1790428911,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nNovel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer  \nEma Mitsui1, Satoru Kikuchi1􀀍, Tomohiro Okura1, Hiroshi Tazawa1,2, Yuta Une1,  \nNoriyuki Nishiwaki1, Shinji Kuroda1, Kazuhiro Noma1, Shunsuke Kagawa1, Toshiaki Ohara1,3, Junko Ohtsuka4, Rieko Ohki4 & Toshiyoshi Fujiwara1  \nCancer-associated fibroblasts (CAFs) are a crucial component in the tumor microenvironment (TME) of peritoneal metastasis (PM), where they contribute to tumor progression and metastasis via secretion of interleukin-6 (IL-6). Here, we investigated the role of IL-6 in PM of gastric cancer (GC) and assessed whether anti-IL-6 receptor antibody (anti-IL-6RAb) could inhibit PM of GC. We conducted immunohistochemical analysis of IL-6 and α-smooth muscle (α-SMA) expressions in clinical samples of GC and PM, and investigated the interactions between CAFs and GC cells in vitro. Anti-tumor effects of anti-IL-6RAb on PM of GC were investigated in an orthotopic murine PM model. IL-6 expression was significantly correlated with α-SMA expression in clinical samples of GC, and higher IL-6 expression in the primary tumor was associated with poor prognosis of GC. Higher IL-6 and α-SMA expressions were also observed in PM of GC. In vitro, differentiation offibroblasts into CAFs and chemoresistance were observed in GC cells cocultured with fibroblasts. Anti-IL-6RAb inhibited the progression of PM in GC cells cocultured with fibroblasts in the orthotopic mouse model but could not inhibit the progression of PM consisting of GC cells alone. IL-6 expression in theTME was associated with poor prognosis of GC, and CAFs were associated with establishment and progression of PM via IL-6. Anti-IL-6RAb could inhibit PM of GC by the blockade of IL-6 secreted by CAFs, which suggests its therapeutic potential for PM of GC.  \nKeywords Peritoneal metastasis, Gastric cancer, Interleukin-6, Cancer-associated fibroblasts, Interleukin-6 receptor antibody  \nSystemic combination chemotherapy with multiple molecular-targeted therapeutic agents and immunotherapy is a standard treatment for gastric cancer (GC) patients who have distant metastasis and recurrence1,2. Peritoneal metastasis (PM) is one of the most common forms of distant metastasis and recurrence of GC, and curative treatment options remain difficult to find because the unique intraperitoneal tumor microenvironment (TME) and peritoneal–plasma barrier impedes the efficacy of conventional systemic chemotherapy3–5. The TME comprises extracellular matrix, endothelial cells, cancer-associated fibroblasts (CAFs), and immune cells, and their interactions are associated with tumor progression and metastasis6,7. CAFs are crucial components of the TME, and as they are related to tumor progression and metastasis, including PM, they are expected to be potential therapeutic targets8–10. We have recently described important roles of CAFs in the establishment and progression of PM in GC9, reported that interleukin-6 (IL-6) secreted by CAFs in the TME was associated with tumor immunosuppression, and also that neutralizing IL-6 in the TME suppressed tumor progression11, 12.  \n1Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. 2Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama 700-8558, Japan. 3Department of Pathology and Experimental Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama 700-8558, Japan.  \n4Laboratory of Fundamental Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan. 􀀍 email: [satorukc@okayama-u.ac.jp](satorukc@okayama-u.ac.jp)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nMoreover, we have shown that intraperitoneal IL-6 concentration was sign","cbCairuOFhornFXm","https://ap.wps.com/l/cbCairuOFhornFXm","pdf",1803793,11,"English","# Background\n## Rationale for targeting IL-6 in peritoneal metastasis\n## Tumor microenvironment and roles of CAFs\n# Methods\n## Immunohistochemical analysis in clinical samples\n## In vitro interaction and co-culture studies\n## Orthotopic murine peritoneal metastasis model\n# Results\n## IL-6 correlates with α-SMA and prognosis\n## CAF-related IL-6 effects and chemoresistance in co-culture\n## Anti-IL-6RAb suppresses metastasis in CAF-containing models\n# Implications","[{\"question\":\"What role do cancer-associated fibroblasts play in gastric cancer peritoneal metastasis?\",\"answer\":\"CAFs contribute to tumor progression and metastasis in the peritoneal tumor microenvironment by secreting interleukin-6 (IL-6).\"},{\"question\":\"How are IL-6 and α-SMA related in clinical gastric cancer samples?\",\"answer\":\"IL-6 expression significantly correlates with α-SMA expression, a marker related to CAFs, and higher IL-6 in primary tumors is associated with poor prognosis.\"},{\"question\":\"Why does anti-IL-6 receptor antibody inhibit peritoneal metastasis in some models but not others?\",\"answer\":\"Anti-IL-6RAb inhibited progression of peritoneal metastasis in orthotopic models where gastric cancer cells were cocultured with fibroblasts, but it did not inhibit models consisting of gastric cancer cells alone, indicating dependence on CAF-derived IL-6.\"}]","Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer | PDF",1790191529,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/950eaae14d1e4e4a516da552ea3ff1a1.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e422931a5667e1a10d48681c10a32a0b.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3918d23666cc8ff4a8f098ff8997bb1.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a1e14578ca94019f776e5b8f8d2b766.webp",980,1287]